Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.53 +3.09%

+$0.08 today

Market cap
$297.72M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.25M

Average 3.81M

ALT EBITDA Margin

EBITDA as a percentage of revenue.

Altimmune, Inc.NASDAQ: ALT

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Over 3 fiscal years it narrowed by 336389.4 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -2862682.9% for the fiscal year ending Dec 2026, down from -212258.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-212258.5%+261801.5 pp YoY
LTMMar 2026
-245200.0%+208560.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter—-1123552.3 pp—
1 year+261801.5 pp-2650424.3 pp-2912225.8 pp
3 years-336389.4 pp+210437.4 pp+546826.8 pp
5 years+212221.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-212258.5%
Year-over-year change
+261801.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ALT compares with its peers on the latest reported figures

  • ALT's LTM Mar 2026 EBITDA Margin of -245200.0% is the lowest of the 6 companies compared; the peer median is -67.3%.
  • Its year-over-year change of +208560.0 pp is the highest of 6, against a peer median of +113.4 pp.
  • Over three fiscal years its change of -336389.4 pp compares with a peer median of -372.4 pp.
ALT Competitors Peer median
EBITDA Margin for ALT and competitors
Company Period LTM level YoY 3-year change
ABUSArbutus Biopharma CorporationLTM Mar 202684.0% +1306.2 pp-76.1 pp
ASMBAssembly Biosciences, Inc.LTM Mar 2026-8.8% +113.4 pp—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-67.3% +67.9 pp+30.0 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-669.6% +2109.2 pp-668.6 pp
IVAInventiva S.A.FY2025-2858.6% -1048.1 pp-2396.4 pp
ALTAltimmune, Inc.LTM Mar 2026-245200.0% +208560.0 pp-336389.4 pp
GPCRStructure Therapeutics Inc.FY2025— ——
INDPIndaptus Therapeutics, Inc.FY2025— ——
BMEABiomea Fusion, Inc.FY2025— ——
Peer median (excluding ALT) -67.3%+113.4 pp-372.4 pp

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.41M(68K)426K20K41K
Cost of Revenue00000
Gross Profit4.41M(68K)426K20K41K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development74.54M70.54M65.8M82.23M66.43M
Selling, General & Admin15.41M17.13M18.14M20.97M28.1M
Operating Expenses101.32M87.67M96.36M103.19M94.53M
Depreciation & Amortization551K493K477K238K112K
EBITDA(96.53M)(84.41M)(87.94M)(94.81M)(87.03M)
EBITDA Margin-2189.0%124130.9%-20642.0%-474060.0%-212258.5%
Operating Income(96.91M)(87.74M)(95.93M)(103.17M)(94.49M)
Operating Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Interest Income203K2.87M7.35M8.07M7.54M
Interest Expense5K8K35K9K1.64M
Other Income / Expenses(176K)2.83M7.48M8.11M5.72M
Income Before Tax(97.09M)(84.91M)(88.45M)(95.06M)(88.77M)
Pre-Tax Margin-2201.6%124867.6%-20762.2%-475295.0%-216522.0%
Income Tax Expense0(197K)00(681K)
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (Basic)(2.35)(1.81)(1.66)(1.34)(1.00)
EPS (Diluted)(2.35)(1.81)(1.66)(1.34)(1.00)
Weighted Avg Shares41.28M46.93M53.25M71M88.1M
Weighted Avg Shares (Diluted)41.28M46.93M53.25M71M88.1M

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.